View Post

Celsion Announces GEN-1 Data Presentation at ASCO-SITC Clinical Immuno-Oncology Symposium

In Clinical Trials by Barbara Jacoby

Source: Celsion CORP From: globenewswire.com Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the oral presentation of data highlighting the safety, clinical response and translational data from its recently completed OVATION I Study. This Phase IB study evaluated patients newly diagnosed with Stage III/IV ovarian cancer and were treated with Celsion’s DNA-based, IL-12 immunotherapy, GEN-1, in combination …

View Post

Chimeric Antigen Receptor (CAR) T-Cell Clinical Trial

In Clinical Trials by Barbara Jacoby

From: mesothelioma.net An exciting new immunotherapy treatment is now being tested in a phase I clinical trial that is still recruiting for participants. This provides a unique opportunity for patients who qualify to get access to an innovative medicine with great promise. Known as CAR T-cell therapy, this new treatment uses gene therapy to modify a patient’s immune system cells. …

View Post

Moving Away From IP Chemotherapy in Advanced Ovarian Cancer

In Clinical Trials by Barbara Jacoby

By: Bradley J. Monk, MD From: onclive.com The treatment of women with advanced-stage epithelial ovarian cancer (EOC) is aggressive surgical cytoreduction and platinum-based combination chemotherapy. The timing and the extent of surgery have direct implications on the selection of subsequent treatment of patients with EOC. Frontline chemotherapeutic regimens have evolved through a series of large multi-institutional randomized clinical trials that …

View Post

AIVITA Completes Treatment of First Patient in Phase 2 Ovarian Cancer Trial

In Clinical Trials by Barbara Jacoby

Source: AIVITA Biomedical, Inc. From: prnewswire.com AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today that its first patient has completed treatment in its multi-center Phase 2 ROOT OF CANCER ovarian cancer trial. The patient has received the eighth and final dose of the study therapy under the guidance of Principal Investigator Dr. Lisa Abaid …

View Post

OncoQuest Lays the Groundwork for Commencement of Phase 3 Study in Frontline Ovarian Cancer

In Clinical Trials by Barbara Jacoby

Source: OncoQuest, Inc. From: prnewswire.com OncoQuest Inc., a privately held, cancer immunotherapy company, has retained the services of IQVIA, a company formed through the merger of IMS Health and Quintiles, to manage OncoQuest’s planned Phase 3 clinical study in frontline ovarian cancer with the company’s lead product candidate, oregovomab, an anti-CA-125 antibody. OncoQuest will collaborate with IQVIA, a leading global …

View Post

Breast Cancer Drug Promising in Phase 3 Trial

In Clinical Trials by Barbara Jacoby

By: Steven Reinberg From: consumer.healthday.com For women with advanced breast cancer who carry the BRCA1 and BRCA2 gene mutations, an experimental drug could improve survival, a new study suggests. The BRCA mutations are linked with a greater risk for aggressive breast and ovarian cancer. The drug, talazoparib, works by blocking an enzyme called poly ADP ribose polymerase (PARP), thus preventing …

View Post

Olaparib Extends PFS in Ovarian Cancer in SOLO-1 Clinical Trial

In Clinical Trials by Barbara Jacoby

By: Sarah Tilyou From: clinicaloncology.com Maintenance therapy with olaparib can reduce the risk for ovarian cancer progression and related death by 70% at three years, according to results of the phase 3 SOLO-1 trial.  The findings, which were presented at the ESMO 2018 Congress (abstract LBA7_PR) and published in The New England Journal of Medicine (2018 Oct 21. [Epub ahead …

View Post

Could even more cancer patients benefit from PARP inhibitors?

In In The News by Barbara Jacoby

By: Arlene Weintraub From: fiercebiotech.com PARP inhibitors like AstraZeneca’s Lynparza and Tesaro’s Zejula have revolutionized the treatment of ovarian cancers with BRCA mutations and are starting to take off in breast cancer treatment too. But the way that these drugs work could make them applicable to many more cancer types, some oncology researchers believe. The latest evidence of that comes from Yale University, …

View Post

Potential new strategy to fight ovarian cancer found

In In The News by Barbara Jacoby

From: bcm.edu A new discovery opens the possibility of developing a novel way to fight ovarian cancer. Researchers at Baylor College of Medicine and the University of Texas MD Anderson Cancer Center have revealed a previously unknown cellular pathway that selectively regulates a mutant protein, called p53-R175H, linked to ovarian cancer growth. The researchers identified a key regulator of this …

View Post

‘Chemo Bath’ Offers New Hope For Cancer Patients

In In The News by Barbara Jacoby

Filed Under:  Chemotherapy, Kristine Johnson, Local TV From: cbslocal.com A diagnosis of stage four ovarian cancer can be devastating, but imagine being told it’s a death sentence. It happened to one local woman, but an experimental procedure not only gave her hope — it saved her life. Isabel Navas now has countless holidays to look forward to, but just over …